Dicerna Pharmaceuticals
75 Hayden Avenue
Lexington
Massachusetts
02421
United States
Tel: 617-621-8097
Website: http://www.dicerna.com/
About Dicerna Pharmaceuticals
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.
Stock Exchange: NASDAQ
Stock Symbol: DRNA
At Dicerna, we interfere to silence genes, fight rare diseases, enhance health and advance science. The goal is to leverage our GalXC™ platform and strategic partnerships to get the drug to the patient as quickly as possible. Dicerna is dedicated to our patients and committed to breaking down barriers that slow progress in rare diseases. Dicerna promotes a “no walls” philosophy that fosters a collaborative culture where all employees are valued and respected. Dicerna interferes to help patients and change lives.
325 articles about Dicerna Pharmaceuticals
-
Dicerna Pharmaceuticals To Ring The NASDAQ Stock Market Closing Bell July 15th
7/11/2014
-
Dicerna Pharmaceuticals Release: Researchers Demonstrate Promise Of Dicerna Investigational Therapy In Preclinical Model Of Primary Hyperoxaluria Type 1 (PH1)
6/30/2014
-
Dicerna Pharmaceuticals To Present At The 9th Annual JMP Securities Healthcare Conference
6/20/2014
-
Dicerna Pharmaceuticals To Present At Upcoming Conferences
5/27/2014
-
Dicerna Pharmaceuticals To Present At Upcoming Conferences
5/27/2014
-
Dicerna Pharmaceuticals Announces First Quarter 2014 Financial And Operational Results
5/14/2014
-
Dicerna Pharmaceuticals To Announce First Quarter 2014 Financial Results And Host Conference Call On May 13, 2014
5/9/2014
-
Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
4/21/2014
-
Dicerna Pharmaceuticals Initiates Phase 1 Study Of DCR-MYC In Patients With Solid Tumors And Hematological Malignancies
4/17/2014
-
Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava As Chief Medical Officer
4/3/2014
-
Dicerna Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial And Operational Results
3/28/2014
-
Dicerna Pharmaceuticals To Present At Future Leaders In The Biotech Industry Conference On March 28, 2014
3/26/2014
-
Dicerna Pharmaceuticals To Announce Fourth Quarter 2013 Financial Results And Host Conference Call On March 27, 2014
3/25/2014
-
Dicerna Pharmaceuticals To Present At Two Upcoming Conferences
3/7/2014
-
Dicerna Pharmaceuticals To Present At Two Upcoming Conferences
3/6/2014
-
Dicerna Pharmaceuticals To Present At 2014 AsiaTIDES Conference
2/24/2014
-
Dicerna Pharmaceuticals To Present At 2014 Leerink Swann and Company Global Healthcare Conference On February 13th
2/7/2014
-
Dicerna Pharmaceuticals Announces Participation In Panel On RNAi Therapeutics At 16th Annual Biotechnology Industry Organization (BIO) CEO And Investor Conference On February 10th
2/5/2014
-
Dicerna Pharmaceuticals Announces Closing Of Initial Public Offering And Exercise Of Option To Purchase Additional Shares
2/5/2014
-
Dicerna Pharmaceuticals Prices Upsized IPO At $15 Per Share
1/30/2014